Provectus Biopharmaceutica-APVCT
13F holders, Q4 2024 (December 31)6holders −1
0new positions
1sold out
$0.12avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Provectus Biopharmaceutica-A (PVCT) in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 1 sold out. The largest holders were Home Federal Bank of Tennessee ($12K), Atlas Wealth LLC ($3K) and Academy Capital Management ($2K).
- Company
- Provectus Biopharmaceutica-A
- CUSIP
- 74373P108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $5K |
All 13F filers, Q3 2024 → Q4 2024: 50,000 shares sold, net −50,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Home Federal Bank of Tennessee | 0.00% | No change | 100,000 | $12K |
| Atlas Wealth LLC | 0.00% | No change | 26,620 | $3K |
| Academy Capital Management | 0.00% | No change | 20,000 | $2K |
| LBMC Investment Advisors, LLC | 0.00% | No change | 20,000 | $2K |
| Financial Symmetry Inc | 0.00% | No change | 10,191 | $1K |
| Huntington National Bank | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PVCT's weight in each manager's 13F, not the share of Provectus Biopharmaceutica-A the manager owns.